Liraglutide Lowers Blood Sugar And Weight In Type 2 Diabetics
Posted Jun 13 2009 12:26am
Two new publications suggest LIRAGLUTIDE, added to an initial oral medication for Type 2 diabetes, is more effective than adding a second oral anti-diabetic medication. LIRAGLUTIDE is a human glucagon-like peptide-1 (GLP-1) analog, similar to BYETTA, and is currently being reviewed by the FDA.
In a recently published issue of Diabetic Medicine, researchers report that adding liraglutide to glimepiride was more effective at lowering blood sugar than either glimepiride monotherapy or glimepiride/rosiglitazone combination therapy. Patients on liraglutide also experienced increased weight benefit and improved beta-cell function compared to the active rosiglitazone (TZD) comparator treatment.
An additional study published recently in Diabetes Care further supports the efficacy and tolerability profile of liraglutide in the early treatment of type 2 diabetes, this time when added to metformin and compared with glimepiride+metformin combination.
Read more about LIRAGLUTIDEhere.
Our office will likely be participating in a clinical trial, later this year, designed primarily to assess LIRAGLUTIDE as a weight-loss agent.
Labels: BYETTA, Incretin Mimetics, LIRAGLUTIDE, Therapy (Type 2), Weight Loss